THINK OF
PrVELPHORO®
Available for your adult patients with end-stage renal disease (ESRD) who are undergoing dialysis1
PrVELPHORO® (sucroferric oxyhydroxide) is indicated for the control of serum phosphorus levels in adult patients with ESRD on dialysis.
VELPHORO is a phosphate binder that does not contain calcium.*
* Clinical significance has not been established.
- Clinical use:
- Efficacy and safety in pediatric population (<18 years of age) have not been evaluated.
- No overall differences in safety or efficacy were observed between subjects ≥65 and younger subjects.
- Contraindications:
- Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
- Patients with hemochromatosis or any other iron accumulation disorders.
- Relevant warnings and precautions:
- Diabetes, hereditary fructose intolerance, glucose-galactose malabsorption, and sucrase-isomaltase insufficiency
- Caution in patients with gastrointestinal issues
- VELPHORO may cause black stools which may mask gastrointestinal bleeding
- Patients with hepatic/biliary/pancreatic disorders/disease
- Monitoring and laboratory tests regarding serum phosphorus and iron
- Pregnant or nursing women
- Less common clinical trial or post-market adverse reactions:
- In the 6-week and 55-week clinical studies, tooth discolouration and product taste were some of the less common (<1%), treatment-related treatment emergent adverse events reported in more than one patient.
- Eosinophilic peritonitis has been listed in post-market spontaneous reports.
- For more information:
- Please consult the Product Monograph at velphoromonograph.ca for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling us at 1-877-341-9245.
- Reference:
- 1. VELPHORO Product Monograph. Otsuka Canada Pharmaceutical Inc.
